26
Sep
Sep
Glioblastoma multiforme is the most common and aggressive primary brain tumor, with an average survival time after diagnosis of less than two years and for which current treatments remain ineffective. In recent years, immunotherapies have given patients hope, albeit with relatively modest success. A team from the University of Geneva (UNIGE) and the University Hospitals […]